The Shotlee Journal
Browse Shotlee articles about Weight Loss.
Showing 9 / 1248 Weight Loss articles
Kris Jenner recently shared her experience with GLP-1 medications, revealing they made her feel unwell. This opens the door to understanding the nuances of these popular drugs and exploring alternative peptide therapies for weight management and overall health.
Novo Nordisk's Wegovy experienced a remarkable 70% sales volume increase in April after significant price adjustments. This development highlights the growing demand for GLP-1 receptor agonists in weight management and the dynamic shifts within the pharmaceutical market.
Rapid weight loss, often aided by GLP-1 medications like Ozempic and Mounjaro, can lead to significant physical transformations. While celebrated, these changes can sometimes include unwelcome skin laxity, commonly referred to as 'Ozempic Face.' This article delves into the causes, expert opinions, and potential solutions for this growing concern.
The weight management sector is a multi-billion dollar market today, not a future opportunity. Eli Lilly, with its groundbreaking tirzepatide (Zepbound), is poised for sustained growth and profitability, making it a compelling investment for those prioritizing durability and real earnings.
New research suggests that the way you eat—whether driven by emotions or external cues—can significantly influence how well GLP-1 medications like Ozempic, Wegovy, and Mounjaro work for weight loss and type 2 diabetes management. Learn what this means for your treatment.
Discover the science behind GLP-1 peptides, including semaglutide and tirzepatide, and their transformative impact on weight management and metabolic health. Learn about popular medications and how they're changing the landscape of health tracking.
Prescription drug coupons can seem like a straightforward way to save money. However, for individuals with health insurance, these discounts can come with unexpected financial implications. This article delves into the nuances of manufacturer-sponsored coupons, their impact on insurance plans, and how to make informed decisions at the pharmacy counter.
Achieving sustainable weight loss is a journey, not a race. This comprehensive guide offers expert advice on nutrition, exercise, and mindset to help you build healthy habits for life.
Eli Lilly's monumental $4.5 billion investment in its Indiana facilities signals a significant ramp-up in production for groundbreaking GLP-1 agonists like Mounjaro and Zepbound, alongside future weight loss and cardiometabolic disease treatments. This expansion is poised to meet surging global demand and solidify Lilly's position at the forefront of pharmaceutical innovation.
